

## **Breakout Session 1: Track A**

# **A Qualitative Examination of Patients' and Clinicians' Perspectives on AI-driven Automated Screening for Cognitive Impairment**

Dr. Alex Federman (Moderator)

*Professor of Medicine, Icahn School of Medicine at Mount Sinai*

Dr. Jalayne Arias

*Associate Professor, Georgia State University*



Icahn School  
of Medicine at  
**Mount  
Sinai**



# A Qualitative Examination of Patients' and Clinicians' Perspectives on AI-driven Automated Screening for Cognitive Impairment

Supplement Award: Natural Language Processing and Automated Speech Recognition to Identify Older Adults with Cognitive Impairment (3R01AG066471-03S1)

**MPI: Alex Federman MD, MPH**

Professor of Medicine, Geriatrics and Palliative Medicine

Division of General Internal Medicine

Icahn School of Medicine at Mount Sinai

New York, NY

Contact: alex.federman@mssm.edu

**MPI: Jalayne J. Arias, JD, MA**

Associate Professor

NextGen Scholar

Department of Health Policies & Behavioral Sciences

School of Public Health

Georgia State University

Contact: jarias@gsu.edu

# Project Summary and Goals

Overarching goal: Generate a novel ethics framework for identifying and addressing ethical barriers to clinical adoption of AI-driven tools for detecting cognitive impairment in primary care settings.

## Methods:

- Semi-structured interviews with research participants recruited through Parent Award
- Focus groups with primary care clinicians
- PRISMA-Scoping Review to characterize existing ethical norms/standards in the literature

# Achieved Goals & Status

- Conducted and completed preliminary analysis of 31 semi-structured interviews with primary care patients (ages  $\geq 55$ )
- Conducted and ongoing analysis of three primary care physician focus groups (N=17 clinicians)
- Completed collection and preliminary analysis of 84 articles for a PRISMA-Scoping Review (~20 articles pending)

# Patient Participants (n=31)

<b>Age</b>	
50-59 years	10%
60-69 years	55%
70-79 years	19%
80-89 years	16%
<b>Female</b>	58%
<b>Race</b>	
Black, non-Hispanic	58%
White, non-Hispanic	23%
Hispanic or Latino	23%
<b>Education</b>	
Some high school	23%
High school graduate or equivalent	13%
Any college or equivalent	42%
Post-graduate degree	19%

# Patients' Perceived Benefits

- Improved outcomes for detection & diagnosis of cognitive impairment
- Improved access to and acceptability of screening procedures (e.g., workflow efficiency)
- Use of AI-screening for decision-making

*I think a machine would be...nonjudgmental...It would just [provide] an objective point of view, not someone who would know me personally. So, I would feel more confident in the machine actually . . .*

# Patients' Concerns

- Technical errors
- Trust in security (privacy/confidentiality)
- Results leading to mental health distress

*You could hack my medical records . . . there are people with conditions that they see as stigmatized. Maybe there's somebody who sees dementia stigmatizing, or humiliating, or they're embarrassed by it...So, that could be - it could be a problem...It's a big institution protecting your data. We all know that there are big institutions, banks, anthem insurers, right, that have been hacked,*

# Clinicians' and Their Experiences with CI Management (N=17)

Professional Role (% , Colum total >100% due to multiple roles held)	
Clinical Care	100%
Precepting	41%
Administration	53%
Research	18%
Confidence... <i>highly or very confident</i>	
administering screening tests for cognitive impairment	75%
conducting a best-practice work-up of newly identified cognitive impairment	47%
providing best-practice medical care for patients with Alzheimer's type dementias	29%
counseling patients and caregivers about non-medical care for people with dementia	35%
Quality/availability of resources for patients with dementia at your institution - <i>excellent or very good</i>	13%
Use or interaction with artificial intelligence (AI)-based tools/support - <i>any</i>	23%




# Clinicians' Perspectives


Benefits	Concerns		
Diagnostic triangulation	Insufficient Resources for follow-up evaluation & care	Bias and inaccuracies	Psychological stress for patients
Efficiency & time saving	Financial/insurance coverage risk for patients	Insufficient knowledge to help patients interpret and trust results	Patient Consent & Autonomy

*I would be skeptical of, which is like my patients have different educational levels. Some of them have different literacy levels. They speak different languages. I worry that like a lot of cognitive tests, at least, that I'm imagining like this fun Lumosity brain games may have images or rely on language-based factors that really are helpful for most people but may not be appropriate for my patient.*


# PRISMA-Scoping Review



# Clinical Use of AI Tool Evaluated in the Literature



# Ethical Standards Are Raised in the Evaluation



■ Autonomy (including consent)

■ Bias

■ Accountability

■ Transparency

■ Other

■ Justice (equity, fairness)


■ Benefits

■ Privacy/Confidentiality

■ Disclosure of results/Return of results to patients


# Bonus: PRISMA-SR (Clinician Acceptance)

Barriers and Facilitators to Clinician AI Acceptance and Use




# Integrated throughout: Consent & Clinical Use of AI

How do we think about the models of consent in the context of different uses of AI Tools to “meet” elements of a valid consent?



## Elements of Informed Consent

- Disclosure of Information
- Capacity to consent
- Voluntary



## Clinical Use

- Screening
- Diagnosis
- Treatment decisions
- Monitoring

# Path for AI-Tool Development Has Multiple Points of Ethical Assessment

Potential harms & unintended consequences flow back to individuals and subgroups (discriminatory interpretations, inequity in access, confidentiality/privacy breach)

Patient  
Data

Participant  
Data


Research/  
Repository/  
Data  
Attainment

Algorithms that  
inform AI-Tool  
Development

Clinical  
Implementatio  
n



# New Model(s) is Needed to Understand the Implementation of AI into Clinical Context





# Challenges & Outputs

- Synthesizing literature that uses varying terms within a quick moving topic area
- Recruitment of clinicians (limited capacity/time)

## **Planned Publications (in Draft)**

- Ethical challenges in machine learning-based clinical screening of cognitive impairment, Arias et al
- Patient perceptions about artificial intelligence in screening for cognitive impairment, Wurtz et al
- Barriers and facilitators to clinician AI acceptance and use in healthcare settings, Scipion et al

# Future Directions

- Developing next proposal to evaluate barriers and solutions to improve physician literacy in AI
- Generate informed consent models that are consistent with and tailored to AI-driven tools for cognitive impairment detection

# Acknowledgements

Funding: R01AG066471, R01AG066471-S1



Mary Manchester, MPH  
Catherine Scipion, MD, MS  
Yufei Wang, MPH  
Kendall Williams  
Ben Wills, MS

*Former:*

Lillian Morgado, MPH  
Tatyana Valteau, MPH



Heather Wurtz, PhD  
Sybil Masse, MPH  
Hannah Hanson, MPH  
Kathryn Marcon, MPH